Seyed Mahdi Hassanian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4907809/publications.pdf Version: 2024-02-01

		109321	144013
131	4,434	35	57
papers	citations	h-index	g-index
131 all docs	131 docs citations	131 times ranked	6886 citing authors

#	Article	IF	CITATIONS
1	The prognostic value of MGMT promoter methylation in glioblastoma: A metaâ€analysis of clinical trials. Journal of Cellular Physiology, 2018, 233, 378-386.	4.1	238
2	MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. European Journal of Cancer, 2016, 53, 25-32.	2.8	159
3	Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer. Current Medicinal Chemistry, 2017, 24, 1321-1331.	2.4	158
4	Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress. Journal of Cellular Biochemistry, 2018, 119, 2460-2469.	2.6	150
5	The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. Journal of Cellular Physiology, 2018, 233, 774-786.	4.1	135
6	Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress. Journal of Cellular Biochemistry, 2017, 118, 1979-1983.	2.6	127
7	Phytosomal curcumin inhibits tumor growth in colitisâ€associated colorectal cancer. Journal of Cellular Physiology, 2018, 233, 6785-6798.	4.1	110
8	The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy. Journal of Cellular Biochemistry, 2017, 118, 4163-4169.	2.6	100
9	Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. Biochimie, 2019, 157, 64-71.	2.6	85
10	Role of Wnt/β atenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer. Journal of Cellular Physiology, 2018, 233, 811-817.	4.1	79
11	Depression and anxiety symptoms are associated with white blood cell count and red cell distribution width: A sex-stratified analysis in a population-based study. Psychoneuroendocrinology, 2017, 84, 101-108.	2.7	78
12	Crocin synergistically enhances the antiproliferative activity of 5â€flurouracil through Wnt/PI3K pathway in a mouse model of colitisâ€associated colorectal cancer. Journal of Cellular Biochemistry, 2018, 119, 10250-10261.	2.6	77
13	Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer. Journal of Cellular Physiology, 2018, 233, 5613-5622.	4.1	76
14	Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives. Journal of Cellular Biochemistry, 2017, 118, 2502-2515.	2.6	70
15	The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. Journal of Cellular Biochemistry, 2018, 119, 213-222.	2.6	70
16	Role of Wnt5a in the Pathogenesis of Inflammatory Diseases. Journal of Cellular Physiology, 2017, 232, 1611-1616.	4.1	69
17	Crocus sativus a natural food coloring and flavoring has potent anti-tumor properties. Phytomedicine, 2018, 43, 21-27.	5.3	66
18	Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. Journal of Cellular Physiology, 2020, 235, 4146-4152.	4.1	64

#	Article	IF	CITATIONS
19	Clinical Significance and Prognosis Value of Wnt Signaling Pathway in Cervical Cancer. Journal of Cellular Biochemistry, 2017, 118, 3028-3033.	2.6	63
20	Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. Journal of Cellular Physiology, 2018, 233, 2058-2066.	4.1	61
21	The diagnostic and prognostic value of red cell distribution width in cardiovascular disease; current status and prospective. BioFactors, 2019, 45, 507-516.	5.4	58
22	Adenosine Regulates the Proinflammatory Signaling Function of Thrombin in Endothelial Cells. Journal of Cellular Physiology, 2014, 229, 1292-1300.	4.1	54
23	The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress. Journal of Cellular Biochemistry, 2018, 119, 111-122.	2.6	51
24	The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. Journal of Cellular Physiology, 2018, 233, 2162-2169.	4.1	49
25	Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer. Journal of Cellular Physiology, 2018, 233, 6337-6345.	4.1	49
26	Genetic susceptibility in cervical cancer: From bench to bedside. Journal of Cellular Physiology, 2018, 233, 1929-1939.	4.1	47
27	The 9p21 locus: A potential therapeutic target and prognostic marker in breast cancer. Journal of Cellular Physiology, 2018, 233, 5170-5179.	4.1	47
28	Phytosomal Curcumin Elicits Anti-tumor Properties Through Suppression of Angiogenesis, Cell Proliferation and Induction of Oxidative Stress in Colorectal Cancer. Current Pharmaceutical Design, 2019, 24, 4626-4638.	1.9	45
29	Phytosomalâ€curcumin antagonizes cell growth and migration, induced by thrombin through AMPâ€Kinase in breast cancer. Journal of Cellular Biochemistry, 2018, 119, 5996-6007.	2.6	44
30	Câ€Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives. Journal of Cellular Physiology, 2017, 232, 2657-2673.	4.1	43
31	The potential therapeutic and prognostic impacts of the câ€MET/HGF signaling pathway in colorectal cancer. IUBMB Life, 2019, 71, 802-811.	3.4	43
32	Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. Journal of Cellular Physiology, 2017, 232, 2931-2937.	4.1	40
33	Tumorâ€derived exosomes: Potential biomarkers and therapeutic target in the treatment of colorectal cancer. Journal of Cellular Physiology, 2019, 234, 12422-12432.	4.1	40
34	Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives. Journal of Cellular Physiology, 2018, 233, 4783-4790.	4.1	39
35	Clinical and prognostic value of the Câ€Met/HGF signaling pathway in cervical cancer. Journal of Cellular Physiology, 2018, 233, 4490-4496.	4.1	38
36	Delivery of oxaliplatin to colorectal cancer cells by folate-targeted UiO-66-NH2. Toxicology and Applied Pharmacology, 2021, 423, 115573.	2.8	38

Seyed Mahdi Hassanian

#	Article	IF	CITATIONS
37	Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives. Journal of Cellular Biochemistry, 2017, 118, 1634-1638.	2.6	37
38	The potential role of regulatory microRNAs of RAS/MAPK signaling pathway in the pathogenesis of colorectal cancer. Journal of Cellular Biochemistry, 2019, 120, 19245-19253.	2.6	37
39	Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress. Journal of Cellular Physiology, 2018, 233, 2928-2936.	4.1	35
40	Role of the transforming growth factorâ€Î² signaling pathway in the pathogenesis of colorectal cancer. Journal of Cellular Biochemistry, 2019, 120, 8899-8907.	2.6	35
41	Role of thrombin in the pathogenesis of atherosclerosis. Journal of Cellular Biochemistry, 2019, 120, 4757-4765.	2.6	35
42	Role of thrombin in the pathogenesis of central nervous system inflammatory diseases. Journal of Cellular Physiology, 2017, 232, 482-485.	4.1	34
43	Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways. Life Sciences, 2020, 249, 117470.	4.3	34
44	Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways. Journal of Cellular Physiology, 2018, 233, 2183-2192.	4.1	33
45	Targeting cancer stem cells as therapeutic approach in the treatment of colorectal cancer. International Journal of Biochemistry and Cell Biology, 2019, 110, 75-83.	2.8	33
46	EWâ€7197 prevents ulcerative colitisâ€associated fibrosis and inflammation. Journal of Cellular Physiology, 2019, 234, 11654-11661.	4.1	33
47	Reactive oxygen species in colorectal cancer: The therapeutic impact and its potential roles in tumor progression via perturbation of cellular and physiological dysregulated pathways. Journal of Cellular Physiology, 2019, 234, 10072-10079.	4.1	33
48	Stem cell therapy: A novel approach for myocardial infarction. Journal of Cellular Physiology, 2019, 234, 16904-16912.	4.1	32
49	The current status and perspectives regarding the clinical implication of intracellular calcium in breast cancer. Journal of Cellular Physiology, 2018, 233, 5623-5641.	4.1	31
50	Diagnostic, prognostic, and therapeutic potency of microRNA 21 in the pathogenesis of colon cancer, current status and prospective. Journal of Cellular Physiology, 2019, 234, 8075-8081.	4.1	31
51	The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications. Current Pharmaceutical Design, 2016, 22, 5730-5737.	1.9	30
52	Genetic Background of Hirschsprung Disease: A Bridge Between Basic Science and Clinical Application. Journal of Cellular Biochemistry, 2018, 119, 28-33.	2.6	29
53	Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. Journal of Cellular Physiology, 2018, 233, 6538-6549.	4.1	29
54	Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer. Current Pharmaceutical Design, 2019, 24, 4605-4610.	1.9	28

#	Article	IF	CITATIONS
55	Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation. Blood, 2015, 125, 1339-1348.	1.4	27
56	Interaction between a variant of CDKN2A/B-gene with lifestyle factors in determining dyslipidemia and estimated cardiovascular risk: A step toward personalized nutrition. Clinical Nutrition, 2018, 37, 254-261.	5.0	27
57	Role of adenosine signaling in the pathogenesis of breast cancer. Journal of Cellular Physiology, 2018, 233, 1836-1843.	4.1	27
58	Therapeutic potency of crocin in the treatment of inflammatory diseases: Current status and perspective. Journal of Cellular Physiology, 2019, 234, 14601-14611.	4.1	27
59	Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy. Journal of Cellular Biochemistry, 2017, 118, 1994-1999.	2.6	26
60	Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives. Journal of Cellular Physiology, 2019, 234, 2329-2336.	4.1	26
61	PNUâ€74654 enhances the antiproliferative effects of 5â€FU in breast cancer and antagonizes thrombinâ€induced cell growth via the Wnt pathway. Journal of Cellular Physiology, 2019, 234, 14123-14132.	4.1	26
62	Therapeutic potential of pharmacological TGF-β signaling pathway inhibitors in the pathogenesis of breast cancer. Biochemical Pharmacology, 2019, 164, 17-22.	4.4	25
63	The crossâ€regulation between SOX15 and Wnt signaling pathway. Journal of Cellular Physiology, 2017, 232, 3221-3225.	4.1	24
64	Role of regulatory miRNAs of the Wnt/ β-catenin signaling pathway in tumorigenesis of breast cancer. Gene, 2020, 754, 144892.	2.2	24
65	Saffron against Components of Metabolic Syndrome: Current Status and Prospective. Journal of Agricultural and Food Chemistry, 2017, 65, 10837-10843.	5.2	23
66	Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatinâ€based chemotherapy. Journal of Cellular Physiology, 2018, 233, 2193-2201.	4.1	23
67	The diagnostic and prognostic value of circulating microRNAs in coronary artery disease: A novel approach to disease diagnosis of stable CAD and acute coronary syndrome. Journal of Cellular Physiology, 2018, 233, 6418-6424.	4.1	23
68	The prognostic value of long noncoding RNA MEG3 expression in the survival of patients with cancer: A metaâ€analysis. Journal of Cellular Biochemistry, 2018, 119, 9583-9590.	2.6	23
69	Role of TGFâ€Î² signaling regulatory microRNAs in the pathogenesis of colorectal cancer. Journal of Cellular Physiology, 2019, 234, 14574-14580.	4.1	23
70	The prognostic potential of long noncoding RNA HOTAIR expression in human digestive system carcinomas: A metaâ€analysis. Journal of Cellular Physiology, 2019, 234, 10926-10933.	4.1	23
71	A genetic variant in CDKN2A/B gene is associated with the increased risk of breast cancer. Journal of Clinical Laboratory Analysis, 2018, 32, .	2.1	22
72	The genetic factors contributing to hypospadias and their clinical utility in its diagnosis. Journal of Cellular Physiology, 2019, 234, 5519-5523.	4.1	22

#	Article	IF	CITATIONS
73	Proinflammatory signaling functions of thrombin in cancer. Journal of Cellular Physiology, 2017, 232, 2323-2329.	4.1	21
74	Adenosine: An endogenous mediator in the pathogenesis of gynecological cancer. Journal of Cellular Physiology, 2018, 233, 2715-2722.	4.1	20
75	The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective. Journal of Cellular Biochemistry, 2018, 119, 7913-7923.	2.6	20
76	The clinical impact of exosomes in cardiovascular disorders: From basic science to clinical application. Journal of Cellular Physiology, 2019, 234, 12226-12236.	4.1	20
77	MicroRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Current Drug Targets, 2019, 20, 1129-1140.	2.1	20
78	Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease. Current Pharmaceutical Design, 2018, 24, 1887-1898.	1.9	19
79	Saffron (<i>Crocus sativus</i>) in the treatment of gastrointestinal cancers: Current findings and potential mechanisms of action. Journal of Cellular Biochemistry, 2019, 120, 16330-16339.	2.6	19
80	Association between non-alcoholic fatty liver disease and colorectal cancer. Expert Review of Gastroenterology and Hepatology, 2019, 13, 633-641.	3.0	19
81	Therapeutic potential of renin angiotensin system inhibitors in cancer cells metastasis. Pathology Research and Practice, 2020, 216, 153010.	2.3	18
82	Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives. Journal of Pharmacy and Pharmacology, 2018, 70, 151-158.	2.4	17
83	Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression. Gene, 2019, 706, 131-139.	2.2	17
84	Targeted therapies in pancreatic cancer: Promises and failures. Journal of Cellular Biochemistry, 2019, 120, 2726-2741.	2.6	17
85	Genetic variation in the DNA repair pathway as a potential determinant of response to platinumâ€based chemotherapy in breast cancer. Journal of Cellular Physiology, 2018, 233, 2752-2758.	4.1	16
86	Therapeutic potency of pharmacological adenosine receptor agonist/antagonist in angiogenesis, current status and perspectives. Journal of Pharmacy and Pharmacology, 2018, 70, 191-196.	2.4	16
87	A genetic variant in <i>CDKN2A/2B</i> locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma. Journal of Cellular Physiology, 2019, 234, 5070-5076.	4.1	16
88	Circulating Exosomes as Potential Biomarkers in Cardiovascular Disease. Current Pharmaceutical Design, 2019, 24, 4436-4444.	1.9	16
89	Current Status and Prospective Regarding the Therapeutic Potential of Natural Autoantibodies in Cancer Therapy. Journal of Cellular Physiology, 2017, 232, 2649-2652.	4.1	15
90	Therapeutic potency of heat-shock protein-70 in the pathogenesis of colorectal cancer: current status and perspectives. Biochemistry and Cell Biology, 2019, 97, 85-90.	2.0	15

Seyed Mahdi Hassanian

#	Article	IF	CITATIONS
91	Therapeutic effects of silver nanoparticle containing sulfasalazine on DSS-induced colitis model. Journal of Drug Delivery Science and Technology, 2021, 61, 102133.	3.0	15
92	Role of Wnt3a in the pathogenesis of cancer, current status and prospective. Molecular Biology Reports, 2019, 46, 5609-5616.	2.3	14
93	Novel oral transforming growth factorâ€Î² signaling inhibitor potently inhibits postsurgical adhesion band formation. Journal of Cellular Physiology, 2020, 235, 1349-1357.	4.1	13
94	Magnetic Amine-Functionalized UiO-66 for Oxaliplatin Delivery to Colon Cancer Cells: In Vitro Studies. Journal of Cluster Science, 2022, 33, 2345-2361.	3.3	13
95	The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer. International Journal of Biochemistry and Cell Biology, 2020, 124, 105765.	2.8	13
96	Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer. Current Pharmaceutical Design, 2018, 24, 2710-2718.	1.9	13
97	Therapeutic Potential of Targeting Transforming Growth Factor-beta in Colorectal Cancer: Rational and Progress. Current Pharmaceutical Design, 2019, 25, 4085-4089.	1.9	13
98	Therapeutic potentials of adenosine receptors agonists and antagonists in colitis; Current status and perspectives. Journal of Cellular Physiology, 2018, 233, 2733-2740.	4.1	12
99	Association of cyclinâ€dependent kinase inhibitor 2A/B with increased risk of developing breast cancer. Journal of Cellular Physiology, 2020, 235, 5141-5145.	4.1	12
100	Epigenetic Drug Therapy in the Treatment of Colorectal Cancer. Current Pharmaceutical Design, 2018, 24, 2701-2709.	1.9	12
101	Role of adenosine signaling in the pathogenesis of head and neck cancer. Journal of Cellular Biochemistry, 2018, 119, 7905-7912.	2.6	11
102	Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective. Journal of Cellular Physiology, 2019, 234, 1295-1299.	4.1	10
103	AMPâ€kinase inhibitor dorsomorphin reduces the proliferation and migration behavior of colorectal cancer cells by targeting the AKT/mTOR pathway. IUBMB Life, 2019, 71, 1929-1936.	3.4	10
104	Therapeutic potential of tollâ€like receptors in treatment of gynecological cancers. IUBMB Life, 2019, 71, 549-564.	3.4	10
105	Renin-angiotensin System Inhibitors and Development of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Current Pharmaceutical Design, 2020, 26, 5079-5085.	1.9	10
106	The 9p21 locus as a potential therapeutic target and prognostic marker in colorectal cancer. Pharmacogenomics, 2018, 19, 463-474.	1.3	9
107	Circulating and tissue microRNAs as a potential diagnostic biomarker in patients with thrombotic events. Journal of Cellular Physiology, 2020, 235, 6393-6403.	4.1	9
108	Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway. Cellular Signalling, 2021, 85, 110069.	3.6	9

#	Article	IF	CITATIONS
109	Crocin as a novel therapeutic agent against colitis. Drug and Chemical Toxicology, 2020, 43, 514-521.	2.3	9
110	Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress. Current Drug Targets, 2019, 20, 1486-1495.	2.1	9
111	Therapeutic potency of oncolytic virotherapy–induced cancer stem cells targeting in brain tumors, current status, and perspectives. Journal of Cellular Biochemistry, 2019, 120, 2766-2773.	2.6	8
112	The therapeutic potential of losartan in lung metastasis of colorectal cancer. EXCLI Journal, 2020, 19, 927-935.	0.7	8
113	Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer. Toxicology and Applied Pharmacology, 2022, 440, 115951.	2.8	8
114	The potential role of adenosine signaling in the pathogenesis of melanoma. Biochemical Pharmacology, 2018, 156, 451-457.	4.4	7
115	Association of a genetic variant in ATPâ€binding cassette subâ€family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus. IUBMB Life, 2019, 71, 1252-1258.	3.4	7
116	Association between genetic variants at 9p21 locus with risk of breast cancer: A systematic review and meta-analysis. Pathology Research and Practice, 2020, 216, 152987.	2.3	7
117	Therapeutic potential of RAS prenylation pharmacological inhibitors in the treatment of breast cancer, recent progress, and prospective. Journal of Cellular Biochemistry, 2019, 120, 6860-6867.	2.6	6
118	Therapeutic potential of active components of saffron in post-surgical adhesion band formation. Journal of Traditional and Complementary Medicine, 2021, 11, 328-335.	2.7	5
119	Metformin inhibits polyphosphate-induced hyper-permeability and inflammation. International Immunopharmacology, 2021, 99, 107937.	3.8	5
120	Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer. EXCLI Journal, 2021, 20, 506-521.	0.7	5
121	Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer. Tissue and Cell, 2022, 77, 101853.	2.2	5
122	Angiotensinâ€converting enzyme gene polymorphism and digestive system cancer risk: A metaâ€analysis based on 9656 subjects. Journal of Cellular Biochemistry, 2019, 120, 19388-19395.	2.6	4
123	Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2851-2865.	2.5	4
124	The prognostic value of long noncoding RNA MEG3 expression in the survival of patients with cancer: A metaâ€analysis—response. Journal of Cellular Biochemistry, 2019, 120, 18599-18599.	2.6	3
125	Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives. Journal of Cellular Physiology, 2019, 234, 1237-1247.	4.1	3
126	Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective. Journal of Cellular Biochemistry, 2019, 120, 2801-2809.	2.6	3

#	Article	IF	CITATIONS
127	Inhibition of transforming growth factor-beta by Tranilast reduces tumor growth and ameliorates fibrosis in colorectal cancer. EXCLI Journal, 2021, 20, 601-613.	0.7	3
128	The genetic factors contributing to the development of Wilm's tumor and their clinical utility in its diagnosis and prognosis. Journal of Cellular Physiology, 2018, 233, 2882-2888.	4.1	2
129	The association between genetic variants in the genes for cytochrome P450 B1 and ATP-binding cassette transporter genes and breast cancer risk. Molecular Biology Reports, 2020, 47, 6009-6014.	2.3	2
130	Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer. EXCLI Journal, 2021, 20, 863-878.	0.7	2
131	Therapeutic Potential of Heat Shock Protein 90 Inhibitors in Colorectal Cancer. Heat Shock Proteins, 2019, , 47-84.	0.2	0